眼科药物市场 - 按治疗类别（抗 VEGF、抗青光眼）、适应症（干眼、过敏）、给药途径（局部）、类型（处方、非处方药）、剂型（眼药水、凝胶）、配销通路, 全球预测，2024 - 2032

由于白内障、青光眼和老年黄斑部病变等眼部疾病和疾病发生率的增加，预计 2024 年至 2032 年眼科药物市场的CAGR将达到 5.1%。世界卫生组织报告称，白内障影响了约6,520万人，其中80%以上的病例导致中度至重度视力丧失。这刺激了对眼科药物的需求，因为这些病症通常需要药物干预来管理或治疗。

此外，该领域持续的研究和创新导致了新疗法和药物的引入，并提高了各种眼部疾病的治疗效果。这些进步不仅满足了现有的医疗需求，还提供了新的和改进的解决方案，从而吸引了医疗保健专业人员和患者。

眼科药品产业根据剂型、治疗类别、适应症、给药途径、产品、配销通路和地区进行细分。

抗发炎药物领域预计在预测期内大幅成长，因为它们有助于控制各种发炎性眼部疾病。发炎是许多眼部疾病的常见因素，例如葡萄膜炎和干眼症。抗发炎药，包括皮质类固醇和非类固醇抗发炎药 (NSAID)，可透过减少发炎和缓解症状来有效解决这些问题。

在近视盛行率不断上升的推动下，近视细分市场将在 2024 年至 2032 年期间为市场带来可观的收入。对数位设备的日益依赖和萤幕时间的延长，尤其是在年轻人中，导致近视病例激增。随着对管理和遏制近视的有效解决方案的需求不断增加，製药公司正在投资研发，从而推出专门满足这一需求的新药。

由于医疗保健意识不断提高，亚太地区眼科药物产业预计到 2032 年将显着成长。眼部疾病的盛行率不断增加，特别是在该地区的老年人口中。快速的城市化和生活方式的改变导致与眼睛相关的疾病激增。此外，医疗保健服务的可近性和对眼睛健康重要性的认识不断提高，促使人们寻求早期诊断和治疗，从而增加了对眼科药物的需求。医疗保健基础设施的进步和对预防保健的日益重视正在刺激区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：眼科药品产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 眼部疾病盛行率增加
    • 与新药开发相关的研究和开发不断增加
    • 诊断和治疗方式的技术进步
    • 提高对眼部疾病的认识
    • 老年人口不断增加
    • 越来越关注开发联合疗法
  • 产业陷阱与挑战
    • 流行药物失去专利保护
    • 发展中国家缺乏健康保险
• 成长潜力分析
• 监管环境
  • 我们
  • 欧洲
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：眼科药物市场规模与预测：依治疗类别，2018-2032 年

• 主要动力向：依治疗类别
• 抗VEGF剂
• 抗青光眼药物
  • α激动剂
  • β受体阻断剂
  • 前列腺素类似物
  • 联合用药
  • 其他抗青光眼药物
• 抗发炎药
  • 类固醇
  • 非类固醇抗发炎药
• 抗感染药
  • 抗菌药物
  • 抗真菌药物
  • 其他抗感染药
• 抗过敏药
• 其他治疗类别

第 6 章：眼科药物市场规模与预测：按适应症分类，2018-2032 年

• 主要动向：依指示
• 干眼症
• 青光眼
• 感染/发炎
• 视网膜疾病
  • 湿AMD
  • 干性AMD
  • 糖尿病性视网膜病变
  • 其他视网膜疾病
• 过敏
• 葡萄膜炎
• 近视
• 下垂症
• FECD
• 色素性视网膜炎
• 其他适应症

第 7 章：眼科药物市场规模与预测：按给药途径，2018-2032 年

• 主要动向：按给药途径
• 专题
• 局部眼部（玻璃体内）
• 其他给药途径

第 8 章：眼科药物市场规模及预测：依产品分类，2018-2032

• 主要动向：按产品
• 处方
• 场外交易

第 9 章：眼科药物市场规模及预测：按剂型，2018-2032

• 主要动力方向：按剂型
• 眼药水
• 胶囊和片剂
• 凝胶
• 药膏
• 注射剂
• 奶油
• 其他剂型

第 10 章：眼科药物市场规模及预测：依配销通路，2018-2032

• 主要动向：按配销通路
• 医院药房
• 零售药局
• 网路药局

第 11 章：眼科药物市场规模及预测：按地区划分，2018-2032

• 主要动向：按地区
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 12 章：公司简介

• AbbVie, Inc.
• Alcon Vision LLC
• Bausch Health Companies, Inc.
• Bayer AG
• Coherus BioSciences
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Pfizer, Inc.
• Regeneron Pharmaceuticals, Inc.
• Santen, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

Ophthalmology Drugs Market is anticipated to record a CAGR of 5.1% from 2024 to 2032, driven by increasing incidences of eye disorders and diseases such as cataracts, glaucoma, and age-related macular degeneration. The World Health Organization report stated that cataracts affected approximately 65.2 million people and caused moderate to severe vision loss in over 80% of cases. This fuels the demand for ophthalmic drugs, as these conditions often require pharmaceutical interventions to manage or treat.

Additionally, ongoing research and innovation in the field lead to the introduction of novel therapies and medications, enhancing the effectiveness of treatments for various eye diseases. These advancements not only address existing medical needs but also offer new and improved solutions, thus attracting both healthcare professionals and patients.

Ophthalmology drugs industry is segmented based on dosage form, therapeutic class, indication, route of administration, product, distribution channel, and region.

Anti-inflammatory drugs segment is poised for substantial growth in the forecast period, as they help in managing various inflammatory eye conditions. Inflammation is a common factor in numerous eye disorders, such as uveitis and dry eye syndrome. Anti-inflammatory drugs, including corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), effectively address these conditions by reducing inflammation and alleviating symptoms.

Myopia segment will generate notable revenues for the market during 2024-2032, propelled by the escalating prevalence of nearsightedness. The increasing reliance on digital devices and prolonged screen time, especially among younger populations, is leading to surge in myopia cases. As the demand for effective solutions to manage and curb myopia rises, pharmaceutical companies are investing in R&D, leading to the introduction of novel drugs that cater specifically to this need.

Asia Pacific ophthalmology drugs industry is slated to witness a significant growth rate through 2032, attributed to rising healthcare awareness. There is an increasing prevalence of eye disorders, notably among the aging population in the region. Rapid urbanization and lifestyle changes contribute to a surge in eye-related conditions. Furthermore, the accessibility to healthcare services and heightened awareness about the importance of eye health are driving individuals to seek early diagnosis and treatment, thereby boosting the demand for ophthalmology drugs. The advancements in healthcare infrastructure and a growing emphasis on preventive care are stimulating the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast parameters
• 1.4 Data validation
• 1.5 Data Sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Global ophthalmology drugs industry 360 degree synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Therapeutic class trends
  • 2.1.4 Indication trends
  • 2.1.5 Route of administration trends
  • 2.1.6 Product trends
  • 2.1.7 Dosage form trends
  • 2.1.8 Distribution channel trends

Chapter 3 Ophthalmology Drugs Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of eye disorders
    • 3.2.1.2 Rising research and development pertaining to the development of novel drugs
    • 3.2.1.3 Technological advances in diagnostic and treatment modalities
    • 3.2.1.4 Increase in awareness of eye disorders
    • 3.2.1.5 Growing geriatric population
    • 3.2.1.6 Increasing focus on developing combination therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Loss of patent protection for popular drugs
    • 3.2.2.2 Lack of health insurance in the developing countries
• 3.3 Growth potential analysis
  • 3.3.1 By therapeutic class
  • 3.3.2 By indication
  • 3.3.3 By route of administration
  • 3.3.4 By product
  • 3.3.5 By dosage form
  • 3.3.6 By distribution channel
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis, 2023
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard, 2023

Chapter 5 Ophthalmology Drugs Market Size and Forecast, By Therapeutic Class, 2018-2032 (USD Million)

• 5.1 Key trends, by therapeutic class
• 5.2 Anti-VEGF agents
• 5.3 Anti-glaucoma drugs
  • 5.3.1 Alpha agonist
  • 5.3.2 Beta blockers
  • 5.3.3 Prostaglandin analogs
  • 5.3.4 Combined medication
  • 5.3.5 Other anti-glaucoma drugs
• 5.4 Anti-inflammatory drugs
  • 5.4.1 Steroids
  • 5.4.2 NSAIDs
• 5.5 Anti-infective drugs
  • 5.5.1 Anti-bacterial drugs
  • 5.5.2 Anti-fungal drugs
  • 5.5.3 Other anti-infective drugs
• 5.6 Anti-allergy drugs
• 5.7 Other therapeutic categories

Chapter 6 Ophthalmology Drugs Market Size and Forecast, By Indication, 2018-2032 (USD Million)

• 6.1 Key trends, by indication
• 6.2 Dry eye
• 6.3 Glaucoma
• 6.4 Infection/inflammation
• 6.5 Retinal disorders
  • 6.5.1 Wet AMD
  • 6.5.2 Dry AMD
  • 6.5.3 Diabetic retinopathy
  • 6.5.4 Other retinal disorders
• 6.6 Allergy
• 6.7 Uveitis
• 6.8 Myopia
• 6.9 Ptosis
• 6.10 FECD
• 6.11 Retinitis pigmentosa
• 6.12 Other indications

Chapter 7 Ophthalmology Drugs Market Size and Forecast, By Route of Administration, 2018-2032 (USD Million)

• 7.1 Key trends, by route of administration
• 7.2 Topical
• 7.3 Local ocular (intravitreal)
• 7.4 Other routes of administration

Chapter 8 Ophthalmology Drugs Market Size and Forecast, By Product, 2018-2032 (USD Million)

• 8.1 Key trends, by product
• 8.2 Prescription
• 8.3 OTC

Chapter 9 Ophthalmology Drugs Market Size and Forecast, By Dosage Form, 2018-2032 (USD Million)

• 9.1 Key trends, by dosage form
• 9.2 Eye drops
• 9.3 Capsules and tablets
• 9.4 Gels
• 9.5 Ointments
• 9.6 Injectables
• 9.7 Cream
• 9.8 Other dosage forms

Chapter 10 Ophthalmology Drugs Market Size and Forecast, By Distribution Channel, 2018-2032 (USD Million)

• 10.1 Key trends, by distribution channel
• 10.2 Hospital pharmacies
• 10.3 Retail pharmacies
• 10.4 Online pharmacies

Chapter 11 Ophthalmology Drugs Market Size and Forecast, By Region, 2018-2032 (USD Million)

• 11.1 Key trends, by region
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
  • 11.4.6 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 Midde East & Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 Rest of Middle East & Africa

Chapter 12 Company Profiles

• 12.1 AbbVie, Inc.
• 12.2 Alcon Vision LLC
• 12.3 Bausch Health Companies, Inc.
• 12.4 Bayer AG
• 12.5 Coherus BioSciences
• 12.6 F. Hoffmann-La Roche Ltd.
• 12.7 Novartis AG
• 12.8 Pfizer, Inc.
• 12.9 Regeneron Pharmaceuticals, Inc.
• 12.10 Santen, Inc.
• 12.11 Sun Pharmaceutical Industries Ltd.
• 12.12 Teva Pharmaceutical Industries Ltd.